Monitor

What just changed and what’s coming. Actual and guided are never confused.

All eventsGuided onlyActual onlyTrial Readout (864)Corporate Filing (685)Label Expansion (60)Guided Milestone (4)Regulatory Action (22)Congress Presentation (19)
250 events
2050-02
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumpt — primary completionest.
Trial Readout · NCT03883360
2032-02-01
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patien — primary completionest.
Trial Readout · NCT07152184
2031-12
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizoph — primary completionest.
Trial Readout · NCT07114874
2030-04-30
Cognitive Strategies in Early Psychosis 1 — primary completionest.
Trial Readout · NCT07231497
2030-04-30
Cognitive Strategies in Early Psychosis 2 — primary completionest.
Trial Readout · NCT07263022
2030-03-08
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC f — primary completionest.
Trial Readout · NCT07424404
2030-02
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT07459647
2029-12-18
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizo — primary completionest.
Trial Readout · NCT07288567
2029-12-01
Stratification and Treatment in Early Psychosis Study - PROMOTE — primary completionest.
Trial Readout · NCT07434973
2029-12
Sex Differences in NMDA-enhancing Treatment of Schizophrenia — primary completionest.
Trial Readout · NCT07122895
2029-11-30
Confirmatory Trial of Gamma Neurofeedback to Improve Working Memory in Schizophr — primary completionest.
Trial Readout · NCT07592169
2029-07
Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT07227818
2029-06-01
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illn — primary completionest.
Trial Readout · NCT06376734
2029-05-01
No Guts No Glory Probiotics — primary completionest.
Trial Readout · NCT07606014
2029-03-01
LB-102 — Adjunctive MDD (Ph2) topline dataguided
Guided Milestone · LB-102
2029-03
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis — primary completionest.
Trial Readout · NCT07459660
2029-01-01
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairm — primary completionest.
Trial Readout · NCT07084831
2028-12
52-week Open Label Safety-Tolerability Study — primary completionest.
Trial Readout · NCT07369154
2028-12
Dual Modulation of Sigma-1 and NMDA Receptors in the Treatment of Schizophrenia — primary completionest.
Trial Readout · NCT06574360
2028-09-23
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japane — primary completionest.
Trial Readout · NCT06882785
2028-09
Stratification and Treatment in Early Psychosis Study -ASSIST — primary completionest.
Trial Readout · NCT07326124
2028-08-01
Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophreni — primary completionest.
Trial Readout · NCT06939088
2028-06-30
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disord — primary completionest.
Trial Readout · NCT05603104
2028-06-30
Ocrelizumab for Psychosis by Autoimmunity — primary completionest.
Trial Readout · NCT03971487
2028-04-30
Neurotransmitters in Treatment Resistant Schizophrenia Patients With add-on Sodi — primary completionest.
Trial Readout · NCT06340789
2028-04-01
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Prob — primary completionest.
Trial Readout · NCT04323566
2028-03-31
Enhancing Social Skills in Schizophrenia Spectrum Disorders - Oxytocin as add-on — primary completionest.
Trial Readout · NCT06881810
2028-03
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia — primary completionest.
Trial Readout · NCT07225712
2028-02-21
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Ps — primary completionest.
Trial Readout · NCT06947941
2028-02-15
LB-102 — ILLUMINATE-1 (Ph2 bipolar depression) topline dataguided
Guided Milestone · LB-102
2028-02
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emrac — primary completionest.
Trial Readout · NCT07145918
2028-02
Stratification and Treatment in Early Psychosis Study - ENHANCE — primary completionest.
Trial Readout · NCT06778564
2028-01
Cromoglicate Adjunctive Therapy for Outpatients With Schizophrenia — primary completionest.
Trial Readout · NCT03794076
2027-12-31
Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in P — primary completionest.
Trial Readout · NCT07309159
2027-12-31
A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psycho — primary completionest.
Trial Readout · NCT07396870
2027-12-31
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophr — primary completionest.
Trial Readout · NCT07045142
2027-12
A Cognitive Mobile Intervention for Motivation in Psychotic Disorders — primary completionest.
Trial Readout · NCT07674914
2027-12
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia — primary completionest.
Trial Readout · NCT06021197
2027-12
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizop — primary completionest.
Trial Readout · NCT06229210
2027-12
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alz — primary completionest.
Trial Readout · NCT06887192
2027-12
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Neg — primary completionest.
Trial Readout · NCT07565428
2027-12
Enhancing Recovery in Early Schizophrenia — primary completionest.
Trial Readout · NCT02926859
2027-11
Randomized Withdrawal Study in Patients With Schizophrenia — primary completionest.
Trial Readout · NCT06961968
2027-11
A Study of Brenipatide in Adult Participants With Schizophrenia — primary completionest.
Trial Readout · NCT07410507
2027-11
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizoph — primary completionest.
Trial Readout · NCT07105098
2027-10-01
LB-102 — NOVA-2 (Ph3 schizophrenia) topline dataguided
Guided Milestone · LB-102 · NCT07363577
2027-10-01
Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders — primary completionest.
Trial Readout · NCT05838560
2027-10
A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Recept — primary completionest.
Trial Readout · NCT07626034
2027-10
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizoph — primary completionest.
Trial Readout · NCT06963034
2027-09
Monotherapy of an NMDA Enhancer for Schizophrenia — primary completionest.
Trial Readout · NCT04745143
2027-09
Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects — primary completionest.
Trial Readout · NCT04987229
2027-08
Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia — primary completionest.
Trial Readout · NCT07288333
2027-07-29
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Ho — primary completionest.
Trial Readout · NCT07467993
2027-06
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizoph — primary completionest.
Trial Readout · NCT07363577
2027-05
A Clinical Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Sch — primary completionest.
Trial Readout · NCT06821945
2027-04-30
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 — primary completionest.
Trial Readout · NCT03194815
2027-04-30
A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia — primary completionest.
Trial Readout · NCT07423546
2027-04-01
D-serine AudRem: R33 Phase — primary completionest.
Trial Readout · NCT05046353
2027-03
Tolerability of MDMA in Schizophrenia — primary completionest.
Trial Readout · NCT05770375
2027-03
Synbiotic Compound to Reduce Symptoms of Schizophrenia — primary completionest.
Trial Readout · NCT04226898
2027-02-01
LB-102 — Adjunctive MDD (Ph2) trial initiationguided
Guided Milestone · LB-102
2027-02
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resista — primary completionest.
Trial Readout · NCT05240976
2027-01-31
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunct — primary completionest.
Trial Readout · NCT06191965
2027-01-01
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1) — primary completionest.
Trial Readout · NCT04589208
2027-01
Accelerated TMS in Psychosis — primary completionest.
Trial Readout · NCT05567848
2026-12-31
A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone — primary completionest.
Trial Readout · NCT06878833
2026-12-31
Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Actin — primary completionest.
Trial Readout · NCT07185815
2026-12-31
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subje — primary completionest.
Trial Readout · NCT07184619
2026-12-15
Efficiency of a Composite Personalised Care on Functional Outcome in Early Psych — primary completionest.
Trial Readout · NCT05796401
2026-12-15
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants ( — primary completionest.
Trial Readout · NCT03817502
2026-12-01
Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia — primary completionest.
Trial Readout · NCT05778591
2026-12
Combination of NMDA-enhancing and Antioxidant Treatments for Schizophrenia — primary completionest.
Trial Readout · NCT04959201
2026-12
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms. — primary completionest.
Trial Readout · NCT06482554
2026-12
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early — primary completionest.
Trial Readout · NCT04411225
2026-11-24
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer — primary completionest.
Trial Readout · NCT06585787
2026-11
Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schi — primary completionest.
Trial Readout · NCT06315972
2026-11
Combination of NMDA-enhancing and Anti-inflammatory Treatments for Schizophrenia — primary completionest.
Trial Readout · NCT04917302
2026-11
A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the T — primary completionest.
Trial Readout · NCT07521683
2026-10-20
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participan — primary completionest.
Trial Readout · NCT06894212
2026-10
Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer — primary completionest.
Trial Readout · NCT05052853
2026-10
A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With — primary completionest.
Trial Readout · NCT07191483
2026-09-30
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled — primary completionest.
Trial Readout · NCT03094429
2026-09
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric — primary completionest.
Trial Readout · NCT05303064
2026-09
Treating Schizophrenia by Correcting Abnormal Brain Development — primary completionest.
Trial Readout · NCT00179465
2026-09
An Open-Label, Single Arm Study of the Efficacy of Accelerated Intermittent Thet — primary completionest.
Trial Readout · NCT06351514
2026-08-30
A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults — primary completionest.
Trial Readout · NCT05622201
2026-08
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inp — primary completionest.
Trial Readout · NCT07038876
2026-07-01
Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral — primary completionest.
Trial Readout · NCT06529029
2026-07
Study on the Efficacy and Safety of QLM1016 in Schizophrenia — primary completionest.
Trial Readout · NCT06799559
2026-06-30
Acetazolamide for Treatment Resistant Schizophrenia — primary completionest.
Trial Readout · NCT04887792
2026-06-30
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and — primary completionest.
Trial Readout · NCT05064319
2026-06-22
AbbVie — 8-K filed
Corporate Filing
2026-06-10
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-06-09
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-06-08
Metformin Treatment on Cognitive Impairment of Schizophrenia — primary completion
Trial Readout · NCT05838573
2026-06
A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in — primary completionest.
Trial Readout · NCT06589817
2026-06
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olan — primary completionest.
Trial Readout · NCT05669742
2026-05-29
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-05-12
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-05-12
AbbVie — 8-K filed
Corporate Filing
2026-05-08
Bristol-Myers — 8-K filed
Corporate Filing
2026-05-06
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-05-01
Lumateperone late_breaking at NEI 2026
Congress Presentation · Lumateperone (Caplyta)
2026-05-01
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-04-30
Bristol-Myers — 8-K filed
Corporate Filing
2026-04-29
AbbVie — 8-K filed
Corporate Filing
2026-04-28
Johnson & Johnson — 8-K filed
Corporate Filing
2026-04-27
NUPLAZID — efficacy supplement approved
Label Expansion · Pimavanserin
2026-04-24
Lumateperone — FDA efficacy supplement (label expansion) (SUPPL17)
Regulatory Action · Lumateperone (Caplyta)
2026-04-24
CAPLYTA — efficacy supplement approved
Label Expansion · Lumateperone (Caplyta)
2026-04-14
Johnson & Johnson — 8-K filed
Corporate Filing
2026-04-06
LB Pharmaceuticals Inc. — S-1 filed
Corporate Filing
2026-04-03
AbbVie — 8-K filed
Corporate Filing
2026-04
A Study of Olanzapine-Samidorphan Tablets in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT06649214
2026-03-26
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-19
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive Kar — primary completionest.
Trial Readout · NCT05304767
2026-03-16
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-10
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-05
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-03-04
AbbVie — 8-K filed
Corporate Filing
2026-03-01
LB-102 poster at SIRS 2026
Congress Presentation · LB-102
2026-03-01
LB-102 oral at SIRS 2026
Congress Presentation · LB-102
2026-03
Study of SPG302 in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT06442462
2026-02-26
AbbVie — 8-K filed
Corporate Filing
2026-02-25
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-02-05
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-02-05
Bristol-Myers — 8-K filed
Corporate Filing
2026-02-04
AbbVie — 8-K filed
Corporate Filing
2026-02
Study of ALTO-101 in Patients With Schizophrenia — primary completionest.
Trial Readout · NCT06502964
2026-02
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schiz — primary completionest.
Trial Readout · NCT05325645
2026-01-30
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone — primary completion
Trial Readout · NCT07575516
2026-01-21
Johnson & Johnson — 8-K filed
Corporate Filing
2026-01-15
Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Di — primary completionest.
Trial Readout · NCT05946486
2026-01-13
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2026-01-12
Bristol-Myers — 8-K filed
Corporate Filing
2026-01-07
AbbVie — 8-K filed
Corporate Filing
2026-01-02
A Study Assessing the Efficacy and Safety of HS-10380 in Hospitalized Adults Wit — primary completion
Trial Readout · NCT07550387
2025-12-31
Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia — primary completionest.
Trial Readout · NCT04761861
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL14)
Regulatory Action · Cariprazine (Vraylar)
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL16)
Regulatory Action · Cariprazine (Vraylar)
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL15)
Regulatory Action · Cariprazine (Vraylar)
2025-12-18
Cariprazine — FDA efficacy supplement (label expansion) (SUPPL17)
Regulatory Action · Cariprazine (Vraylar)
2025-12-18
VRAYLAR — efficacy supplement approved
Label Expansion · Cariprazine (Vraylar)
2025-11-25
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use — primary completion
Trial Readout · NCT04105231
2025-11-18
Bristol-Myers — 8-K filed
Corporate Filing
2025-11-13
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-12
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-10
Bristol-Myers — 8-K filed
Corporate Filing
2025-11-06
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-05
Lumateperone — FDA efficacy supplement (label expansion) (SUPPL16)
Regulatory Action · Lumateperone (Caplyta)
2025-11-05
CAPLYTA — efficacy supplement approved
Label Expansion · Lumateperone (Caplyta)
2025-11-05
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-11-03
Bristol-Myers — 8-K filed
Corporate Filing
2025-11-03
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-10-31
AbbVie — 8-K filed
Corporate Filing
2025-10-30
Bristol-Myers — 8-K filed
Corporate Filing
2025-10-14
Johnson & Johnson — 8-K filed
Corporate Filing
2025-10-07
Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia — primary completion
Trial Readout · NCT07116694
2025-10-06
Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerabilit — primary completion
Trial Readout · NCT04578756
2025-10-03
AbbVie — 8-K filed
Corporate Filing
2025-10-01
Lumateperone poster at ECNP 2025
Congress Presentation · Lumateperone (Caplyta)
2025-10-01
LB-102 poster at ECNP 2025
Congress Presentation · LB-102
2025-10-01
LB-102 poster at ECNP 2025
Congress Presentation · LB-102
2025-10-01
LB-102 poster at ECNP 2025
Congress Presentation · LB-102
2025-09-12
LB Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-09-12
LB Pharmaceuticals Inc. — 424B4 filed
Corporate Filing
2025-09-11
AbbVie — 8-K filed
Corporate Filing
2025-09-09
Johnson & Johnson — 8-K filed
Corporate Filing
2025-08-22
LB Pharmaceuticals Inc. — S-1 filed
Corporate Filing
2025-08-15
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and — primary completion
Trial Readout · NCT05658510
2025-08-06
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-08
A Long-term Administration Trial of Brexpiprazole Once-weekly (QW) Formulation i — primary completionest.
Trial Readout · NCT05326347
2025-08
Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia — primary completionest.
Trial Readout · NCT06387771
2025-07-31
Bristol-Myers — 8-K filed
Corporate Filing
2025-07-31
AbbVie — 8-K filed
Corporate Filing
2025-07-25
Bristol-Myers — 8-K filed
Corporate Filing
2025-07-16
Johnson & Johnson — 8-K filed
Corporate Filing
2025-07-03
AbbVie — 8-K filed
Corporate Filing
2025-06-30
A Study of ANAVEX3-71 in Adults With Schizophrenia — primary completionest.
Trial Readout · NCT06245213
2025-06-25
A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Pa — primary completion
Trial Readout · NCT05443724
2025-06-20
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Sym — primary completion
Trial Readout · NCT05838625
2025-06-13
An Extension Study of a Second Course of a Digital Therapeutic for the Treatment — primary completion
Trial Readout · NCT06067984
2025-06-10
Johnson & Johnson — 8-K filed
Corporate Filing
2025-06-10
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-29
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-20
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-13
AbbVie — 8-K filed
Corporate Filing
2025-05-09
Brexpiprazole — FDA efficacy supplement (label expansion) (SUPPL14)
Regulatory Action · Brexpiprazole (Rexulti)
2025-05-09
REXULTI — efficacy supplement approved
Label Expansion · Brexpiprazole (Rexulti)
2025-05-07
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-05-07
Bristol-Myers — 8-K filed
Corporate Filing
2025-05-01
LB-102 poster at ASCP 2025
Congress Presentation · LB-102
2025-04-30
Johnson & Johnson — 8-K filed
Corporate Filing
2025-04-25
AbbVie — 8-K filed
Corporate Filing
2025-04-24
Bristol-Myers — 8-K filed
Corporate Filing
2025-04-22
Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance — primary completion
Trial Readout · NCT03238326
2025-04-16
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-04-15
Johnson & Johnson — 8-K filed
Corporate Filing
2025-04-09
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated W — primary completion
Trial Readout · NCT05686239
2025-04-03
Johnson & Johnson — 8-K filed
Corporate Filing
2025-04-03
AbbVie — 8-K filed
Corporate Filing
2025-04-02
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-04-01
LB-102 poster at SIRS 2025
Congress Presentation · LB-102
2025-04-01
R33: Levetiracetam in Early Psychosis — primary completion
Trial Readout · NCT04317807
2025-03-30
Memantine Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion
Trial Readout · NCT04857983
2025-03-27
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-03-19
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inade — primary completion
Trial Readout · NCT05145413
2025-03-18
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-03-13
Study to Assess Safety and Effectiveness of Slowly Increasing Dose and Food Effe — primary completion
Trial Readout · NCT06572449
2025-03-03
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-02-28
Supportive Psychotherapy as Adjunct to Risperidone for Cognitive Function and In — primary completion
Trial Readout · NCT07477301
2025-02-26
Johnson & Johnson — 8-K filed
Corporate Filing
2025-02-26
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2025-02-26
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who — primary completion
Trial Readout · NCT05211947
2025-02-26
AbbVie — 8-K filed
Corporate Filing
2025-02-21
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-02-20
Johnson & Johnson — 8-K filed
Corporate Filing
2025-02-19
AbbVie — 8-K filed
Corporate Filing
2025-02-18
Bristol-Myers — 8-K filed
Corporate Filing
2025-02-14
AbbVie — 8-K filed
Corporate Filing
2025-02-06
Bristol-Myers — 8-K filed
Corporate Filing
2025-02-05
AbbVie — 8-K filed
Corporate Filing
2025-02-04
Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as — primary completion
Trial Readout · NCT05110157
2025-02
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia — primary completionest.
Trial Readout · NCT05184335
2025-01-31
AbbVie — 8-K filed
Corporate Filing
2025-01-30
Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Dis — primary completionest.
Trial Readout · NCT04529226
2025-01-22
Johnson & Johnson — 8-K filed
Corporate Filing
2025-01-13
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-01-13
Bristol-Myers — 8-K filed
Corporate Filing
2025-01-10
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2025-01-10
AbbVie — 8-K filed
Corporate Filing
2025-01-06
AbbVie — 8-K filed
Corporate Filing
2024-12-30
Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia — primary completion
Trial Readout · NCT04414930
2024-12-20
Cognitive Effects of Adjuvant Vortioxetine in Early Schizophrenia — primary completionest.
Trial Readout · NCT04895488
2024-12-13
AbbVie — 8-K filed
Corporate Filing
2024-12-11
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-12-04
Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB — primary completion
Trial Readout · NCT06179108
2024-12-03
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-12-02
The Sub-Sero Study — primary completion
Trial Readout · NCT03994965
2024-12-01
Lumateperone presentation at ACNP 2024
Congress Presentation · Lumateperone (Caplyta)
2024-11-20
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-11-06
ACADIA Pharmaceuticals Inc. — 8-K filed
Corporate Filing
2024-11-05
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-11
Clinical Intervention on Cognitive Impairment of Schizophrenia With Metabolic Sy — primary completionest.
Trial Readout · NCT04518319
2024-10-31
Bristol-Myers — 8-K filed
Corporate Filing
2024-10-30
Intra-Cellular Therapies, Inc. — 8-K filed
Corporate Filing
2024-10-30
AbbVie — 8-K filed
Corporate Filing
2024-10-28
CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in Peo — primary completion
Trial Readout · NCT04860830
2024-10-18
Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schi — primary completion
Trial Readout · NCT04846881
2024-10-15
Johnson & Johnson — 8-K filed
Corporate Filing